Table 2 Clinical characteristics of the patients enrolled for the validation study.
From: Neutrophil degranulation interconnects over-represented biological processes in atrial fibrillation
All n = 39 | Non-AF n = 20 | AF n = 19 | p-value | |
|---|---|---|---|---|
Surgery type | ||||
VATS PVI | – | 19 | ||
CABG | 13 (65) | – | ||
Aortic valve | 4 (20) | – | ||
CABG + valve | 3 (15) | – | ||
Baseline | ||||
Sex, male, n (%) | 28 (72) | 14 (70) | 14 (74) | 1.00 |
Age, years (± SD) | 64 ± 6.8 | 65.8 ± 7.0 | 62.1 ± 6.1 | 0.09 |
AF duration, years [IQ] | – | – | 0 [0–5.25] | NA |
Previous catheter PVI, n (%) | – | – | 2 (5) | NA |
BMI, kg/m2 (± SD) | 27.9 ± 3.4 | 28.2 ± 3.5 | 27.6 ± 3.4 | 0.63 |
Creatinine, μml/l (± SD) | 85.3 ± 12.9 | 86.2 ± 15 | 74.4 ± 11.2 | 0.68 |
CRP, mg/L [IQ] | 2.7 [0.9–2.4] | 1.4 [1.0–2.0] | 1.9 [0.78–3.4] | 1.00 |
CHA2DS2-VASc [IQ] | 2 [1–3] | 3 [2–3] | 1 [1–2] | < 0.01 |
Vascular disease, n (%) | 21 (54) | 17 (85) | 4 (21) | < 0.01 |
Previous PCI, n (%) | 8 (21) | 6 (30) | 2 (11) | 0.24 |
Myocardial infarction, n (%) | 10 (26) | 7 (35) | 3 (16) | 0.27 |
Hypertension, n (%) | 19 (49) | 12 (60) | 7 (37) | 0.21 |
Diabetes Mellitus, n (%) | 5 (13) | 4 (20) | 1 (5) | 0.34 |
Congestive heart failure, n (%) | 0 | 0 | 0 | NA |
Stroke/TIA/embolus, n (%) | 5 (13) | 4 (20) | 1 (5) | 0.34 |
Hematology | ||||
Leukocytes, 10–9/L [IQ] | 6.7 [5.6–8.6] | 8.0 [6.0–9.5] | 5.7 [4.8–7.5] | < 0.05 |
Thrombocytes, 10–9/L [IQ] | 225.5 [205.5–264.3] | 241.5 [214–281.3] | 206.5 [196.3–258.5] | 0.16 |
Medication | ||||
NOAC/vitK antagonist, n (%) | 19 (49) | 0 (0) | 19 (100) | NA |
Antiplatelet, n (%) | 18 (46) | 18 (90) | 0 (0) | NA |
Carbasalate calcium | 16 (41) | 16 | 0 (0) | NA |
Clopidogrel | 5 (13) | 5 | 0 (0) | NA |
Ticagrelor | 1 (3) | 1 | 0 (0) | NA |
Class IA AAD, n (%) | 0 | 0 | 0 | NA |
Class IC AAD, n (%) | 3 (8) | 0 | 3 (16) | 0.11 |
Class II AAD, n (%) | 22 (57) | 13 (65) | 9 (47) | 0.34 |
Class III AAD, n (%) | 9 (23) | 1 (5) | 8 (42) | < 0.01 |
Class IV AAD, n (%) | 0 | 0 | 0 | NA |
Digoxin, n (%) | 4 (10) | 0 | 4 (21) | < 0.05 |
Statins, n (%) | 20 (51) | 13 (65) | 7 (35) | 0.11 |
NSAIDs, n (%) | 2 (5) | 1 (5) | 1 (5) | NA |
Steroids, n (%) | 0 (0) | 0 (0) | 0 (0) | NA |
